Literature DB >> 312670

Separation of blast cell and T-lymphocyte progenitors in the blood of patients with acute myeloblastic leukemia.

M D Minden, R N Buick, E A McCulloch.   

Abstract

The peripheral blood of acute myeloblastic leukemia (AML) patients often contains large numbers of two distinct cell populations, both capable of forming colonies in culture under similar conditions. The first population consists of the precursors of blast cells and has specificity for AML; the second population consists of T-lymphocyte precursors, also found in normal blood. The two progenitor populations can be separated by exploiting the capacity of T-lymphocyte (but not blasts) progenitors to form rosettes with sheep erythrocytes (E rosettes). After E-rosette formation, T-lymphocyte precursors can be removed by centrifugation on Ficoll-Hypaque. Such separation has a number of consequences: (1) Blast progenitors can be detected where unseparated mononuclear preparations have yielded either no colonies or only T-lymphocyte colonies (20 of 21 patients). (2) The stimulator requirements of the blast progenitors change, indicating that cell-cell interactions may take place between blast and T-lymphocyte progenitors. (3) It is feasible to characterize blast and T-lymphocyte precursors independently, even though they may coexist in peripheral blood. This may be important if progenitor properties are attributes contributing to the variance in outcome in AML.

Entities:  

Mesh:

Year:  1979        PMID: 312670

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  [Tumor stem cell research - basis and challenge for diagnosis and therapy].

Authors:  Heidrun Karlic; Harald Herrmann; Axel Schulenburg; Thomas W Grunt; Sylvia Laffer; Irina Mirkina; Rainer Hubmann; Medhat Shehata; Brigitte Marian; Edgar Selzer; Michael Pfeilstöcker; Elisabeth Pittermann; Ulrich Jäger; Hubert Pehamberger; Christoph Zielinski; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2010-07-22       Impact factor: 1.704

2.  Sensitivity of CFU-GM from normal human bone marrow and leukaemic clonogenic cells (CFU-L) from blood of patients with myelogenous leukaemia to 3'-deoxy-3'-fluorothymidine in comparison to 3'-azido-3'-deoxythymidine.

Authors:  I W Blau; E Elstner; M Waechter; R Ihle; M von Janta-Lipinski; P Langen
Journal:  Blut       Date:  1989-11

3.  1,25-Dihydroxyvitamin D3 and its analogues inhibit acute myelogenous leukemia progenitor proliferation by suppressing interleukin-1beta production.

Authors:  S Peleg; H Qiu; S Reddy; D Harris; Q Van; E H Estey; M Talpaz; Z Estrov
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

4.  Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.

Authors:  Geoffrey A Bartholomeusz; Moshe Talpaz; Vaibhav Kapuria; Ling Yuan Kong; Shimei Wang; Zeev Estrov; Waldemar Priebe; Ji Wu; Nicholas J Donato
Journal:  Blood       Date:  2007-01-03       Impact factor: 22.113

5.  Acute nonlymphocytic leukemia (M2) with chromosome abnormality trisomy 4 developing eight years after radiation therapy for breast cancer.

Authors:  S Yokota; M Taniwaki; T Okuda; T Maekawa; K Nishida; S Misawa; T Takino; T Abe; Y Urata
Journal:  Blut       Date:  1989-01

6.  Lymphoma cell culture under serum-free conditions.

Authors:  Y C Dai; X H Wang; N Jamal; H A Messner
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-08       Impact factor: 2.416

Review 7.  Stem cells in melanoma development.

Authors:  Marianna Sabatino; David F Stroncek; Harvey Klein; Francesco M Marincola; Ena Wang
Journal:  Cancer Lett       Date:  2008-12-17       Impact factor: 8.679

8.  Production of erythroid-potentiating activity by a human T-lymphoblast cell line.

Authors:  D W Golde; N Bersch; S G Quan; A J Lusis
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

9.  Adenosine and deoxyadenosine toxicity in colony assay systems for human T-lymphocytes, B-lymphocytes, and granulocytes.

Authors:  L W Brox; E Pollock; A Belch
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.

Authors:  Stefan Faderl; Ashutosh Pal; William Bornmann; Maher Albitar; David Maxwell; Quin Van; Zhenghong Peng; David Harris; Zhiming Liu; Inbal Hazan-Halevy; Hagop M Kantarjian; Zeev Estrov
Journal:  Cancer Res       Date:  2009-04-21       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.